128 related articles for article (PubMed ID: 36334988)
1. Pilot study for the treatment of cutaneous neurofibromas in neurofibromatosis type 1 patients using topical sirolimus gel.
Wataya-Kaneda M; Watanabe Y; Nakamura A; Yamamoto K; Okada K; Maeda S; Nimura K; Saga K; Katayama I
J Am Acad Dermatol; 2023 Apr; 88(4):877-880. PubMed ID: 36334988
[No Abstract] [Full Text] [Related]
2. Topical sirolimus as an effective treatment for a deep neurofibroma in a patient with neurofibromatosis type I.
Malhotra N; Levy JMS; Fiorillo L
Pediatr Dermatol; 2019 May; 36(3):360-361. PubMed ID: 30828862
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis type 1: Factors associated with flare-ups of cutaneous neurofibromas at puberty.
Skayem C; Fertitta L; Diaz E; Jannic A; Ferkal S; Ravaud P; Tran VT; Ezzedine K; Wolkenstein P
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e158-e159. PubMed ID: 36226401
[No Abstract] [Full Text] [Related]
4. A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas.
Blakeley JO; Le LQ; Lee SY; Ly I; Rhodes SD; Romo CG; Sarin KY; Staedtke V; Steensma MR; Wolkenstein P;
J Invest Dermatol; 2023 Aug; 143(8):1351-1357. PubMed ID: 37354152
[No Abstract] [Full Text] [Related]
5. Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1.
Br J Dermatol; 2024 Jan; 190(2):e20. PubMed ID: 38262593
[No Abstract] [Full Text] [Related]
6. How to score the impact of treatment on cutaneous neurofibromas in clinical trials.
Ortonne N
Br J Dermatol; 2024 Jan; 190(2):147-148. PubMed ID: 38084905
[No Abstract] [Full Text] [Related]
7. Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Cannon A; Sarin KY; Petersen AK; Pichard DC; Wolters PL; Erickson G; Lessing AJ; Li P; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR
Clin Trials; 2024 Feb; 21(1):67-72. PubMed ID: 37269078
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
[TBL] [Abstract][Full Text] [Related]
9. [Cosmetic and functional results after resection of cutaneous neurofibroma in neurofibromatosis type 1 : Operation of neurofibroma improves quality of life while having moderate complications].
Walz B; Pfefferle V; Häfner HM; Kofler L
Dermatologie (Heidelb); 2022 Dec; 74(12):961-968. PubMed ID: 37728798
[TBL] [Abstract][Full Text] [Related]
10. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sarin KY; Bradshaw M; O'Mara C; Shahryari J; Kincaid J; Kempers S; Tu JH; Dhawan S; DuBois J; Wilson D; Horwath P; de Souza MP; Powala C; Kochendoerfer GG; Plotkin SR; Webster GF; Le LQ
Sci Adv; 2024 May; 10(18):eadk4946. PubMed ID: 38691597
[TBL] [Abstract][Full Text] [Related]
11. Melanocytic nevi are associated with neurofibromas in neurofibromatosis, type I, but not sporadic neurofibromas: a study of 226 cases.
Ball NJ; Kho GT
J Cutan Pathol; 2005 Sep; 32(8):523-32. PubMed ID: 16115049
[TBL] [Abstract][Full Text] [Related]
12. [Exclusive nodular plexiform neurofibroma. An unusual case of neurofibromatosis type 1].
Benchikhi H; Zeller J; Wolkenstein P; Wechsler J; Vidaud D; Revuz J
Ann Dermatol Venereol; 1995; 122(9):601-3. PubMed ID: 8745684
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study.
Cannon A; Chen MJ; Li P; Boyd KP; Theos A; Redden DT; Korf B
Orphanet J Rare Dis; 2018 Feb; 13(1):31. PubMed ID: 29415745
[TBL] [Abstract][Full Text] [Related]
14. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
Maguiness S; Berman Y; Rubin N; Dodds M; Plotkin SR; Wong C; Moertel C;
Neurology; 2021 Aug; 97(7 Suppl 1):S25-S31. PubMed ID: 34230204
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
Weiss B; Widemann BC; Wolters P; Dombi E; Vinks AA; Cantor A; Korf B; Perentesis J; Gutmann DH; Schorry E; Packer R; Fisher MJ
Pediatr Blood Cancer; 2014 Jun; 61(6):982-6. PubMed ID: 24851266
[TBL] [Abstract][Full Text] [Related]
16. Association of urticaria pigmentosa with café-au-lait spots, neurofibromas and neurofibroma-like neoplasms: a mere coincidence?
Möhrenschlager M; Engst R; Müller-Weihrich S; Spiessl W; Rüdisser K; Weigl LB; Jessberger B; Braun-Falco M; Abeck D; Ring J
Dermatology; 2003; 206(4):297-302. PubMed ID: 12771469
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous angiomyolipoma masquerading as a neurofibroma in a child with neurofibromatosis type 1: a case report.
Carrau D; Kahwash S; Pearson G
Pediatr Dermatol; 2015; 32(3):423-4. PubMed ID: 25640861
[TBL] [Abstract][Full Text] [Related]
18. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas.
Hua C; Zehou O; Ducassou S; Minard-Colin V; Hamel-Teillac D; Wolkenstein P; Valeyrie-Allanore L
Pediatrics; 2014 Jun; 133(6):e1792-7. PubMed ID: 24864177
[TBL] [Abstract][Full Text] [Related]
20. A high-throughput molecular data resource for cutaneous neurofibromas.
Gosline SJ; Weinberg H; Knight P; Yu T; Guo X; Prasad N; Jones A; Shrestha S; Boone B; Levy SE; La Rosa S; Guinney J; Bakker A
Sci Data; 2017 Apr; 4():170045. PubMed ID: 28398289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
